Soluble Thrombomodulin and Brain Infarction: Case–Control and Prospective Study
暂无分享,去创建一个
[1] J. Martí-Fàbregas,et al. Risk of Ischemic Stroke Associated With Functional Thrombin-Activatable Fibrinolysis Inhibitor Plasma Levels , 2003, Stroke.
[2] E. Boerwinkle,et al. Interaction Between Soluble Thrombomodulin and Intercellular Adhesion Molecule-1 in Predicting Risk of Coronary Heart Disease , 2003, Circulation.
[3] Hugh S Markus,et al. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. , 2003, Brain : a journal of neurology.
[4] G. Hallmans,et al. Prospective Study on Soluble Thrombomodulin and von Willebrand Factor and the Risk of Ischemic and Hemorrhagic Stroke , 2002, Thrombosis and Haemostasis.
[5] J. Olivot,et al. Thrombomodulin Prolongs Thrombin-Induced Extracellular Signal—Regulated Kinase Phosphorylation and Nuclear Retention in Endothelial Cells , 2001, Circulation research.
[6] Berislav V. Zlokovic,et al. Anti-Inflammatory, Antithrombotic, and Neuroprotective Effects of Activated Protein C in a Murine Model of Focal Ischemic Stroke , 2001, Circulation.
[7] L. Bajzar. Thrombin Activatable Fibrinolysis Inhibitor and an Antifibrinolytic Pathway , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[8] Blann Ad,et al. von Willebrand factor and soluble thrombomodulin as predictors of adverse events among subjects with peripheral or coronary atherosclerosis. , 1999 .
[9] V. Salomaa,et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atheroscierosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study , 1999, The Lancet.
[10] José A Fernández,et al. Brain-specific protein C activation during carotid artery occlusion in humans. , 1999, Stroke.
[11] J. Loscalzo,et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. , 1998, Blood.
[12] S. Schreiber,et al. Thrombomodulin expression in bovine brain capillaries. Anticoagulant function of the blood-brain barrier, regional differences, and regulatory mechanisms. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[13] C. McCollum,et al. Prognostic value of increased soluble thrombomodulin and increased soluble E‐selectin in ischaemic heart disease , 1997, European journal of haematology.
[14] J. Jansson,et al. Increased levels of plasma thrombomodulin are associated with vascular and all-cause mortality in patients on long-term anticoagulant treatment. , 1996, European heart journal.
[15] J. Manson,et al. Prospective study of endogenous tissue plasminogen activator and risk of stroke , 1994, The Lancet.
[16] H. Ishii,et al. Soluble Thrombomodulin Antigen in Conditioned Medium Is Increased by Damage of Endothelial Cells , 1991, Thrombosis and Haemostasis.
[17] C. Esmon,et al. Thrombomodulin blocks the ability of thrombin to activate platelets. , 1983, The Journal of biological chemistry.
[18] C. Esmon,et al. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[19] A. Blann,et al. von Willebrand factor and soluble thrombomodulin as predictors of adverse events among subjects with peripheral or coronary atherosclerosis. , 1999, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.